Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Kyowa Hakko Kirin to study immuno-oncology therapy

Pfizer and Kyowa Hakko Kirin to study immuno-oncology therapy

3rd October 2014

Pfizer has announced that it will be allying with Kyowa Hakko Kirin to explore the therapeutic potential of a new immuno-oncology combination therapy.

The companies will assess the use of Pfizer's PF-05082566 alongside Kyowa Hakko Kirin's mogamulizumab in a phase Ib clinical study evaluating the safety and tolerability of the combination in patients with solid tumours.

Both firms will provide funding for the trial, which will be conducted by Pfizer. It is expected to establish a recommended dose regimen and assess the safety and preliminary efficacy of the combination.

The study is expected to begin in 2015, with its results set to determine the direction of the future clinical development of the therapy.

Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs and chief medical officer for Pfizer Oncology, said: "We believe that combination therapy in immuno-oncology holds great promise to improve outcomes for patients with cancer and provides an exciting opportunity for Pfizer to maximise the potential of our emerging immuno-oncology portfolio."

Last month, the company announced the completion of its takeover of InnoPharma, thus strengthening its sterile injectables pipeline considerably.ADNFCR-8000103-ID-801752453-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.